Einzeltreffer — DigiBib

The invention provides methods of screening test compounds for their ability to reduce retention of atherogenic lipoproteins in atherogenesis by measuring their activity as a modulator of the binding affinity of CEL (Carboxyl Ester Lipase) to various receptors. The invention further provides methods for the use of active modulators of the binding affinity of CEL to receptors for the prevention and treatment of atherosclerosis.

Titel:	Method
Autor/in / Beteiligte Person:	Bjursell, Karl Gunnar ; Nilsson, Jeanette Annika ; Ellmark, Sara
Link:	Diesen Eintrag von USPTO anschauen (Volltext)
Veröffentlichung:	2008
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20080262108 Publication Date: October 23, 2008 Appl. No: 10/599588 Application Filed: April 01, 2005 Claim: 1. A method of identifying a compound useful for prevention and treatment of atherosclerosis which comprises assaying the compound for its ability to modulate the binding affinity of CEL to a receptor. Claim: 2. A method of identifying a compound useful for reducing the retention of atherogenic lipoproteins in atherogenesis which comprises assaying the compound for its ability to modulate the binding affinity of CEL to a receptor. Claim: 3. A method for reducing the retention of atherogenic lipoproteins in atherogenesis comprising the administration of an effective amount of a modulator of the binding affinity of CEL to a receptor. Claim: 4. A method for the provision of an agent for the reduction of the retention of atherogenic lipoproteins in atherogenesis, which method comprises using one or more putative modulator of the binding affinity of CEL to a receptor as test compounds in one or more procedure to measure the ability of the test compound to reduce the retention of atherogenic lipoproteins, and selecting an active compound for use as an agent able to reduce the retention of atherogenic lipoproteins in atherogenesis. Claim: 5. Use of a modulator of the binding affinity of CEL to a receptor as an agent able to reduce the retention of atherogenic lipoproteins in atherogenesis and thereby preventing or treating atherosclerosis. Claim: 6. A method of preventing or treating atherosclerosis which method comprises administering to a patient in need thereof a pharmaceutically effective amount of an agent able to reduce the retention of atherogenic lipoproteins and thereby preventing or treating atherosclerosis. Claim: 7. (canceled) Claim: 8. Use of an agent able to reduce the retention of atherogenic lipoproteins by modulating the binding affinity of CEL to a receptor in preparation of a medicament for the prevention or treatment of atherosclerosis. Claim: 9. A method of preparing a pharmaceutical composition which comprises: (i) identifying an agent as useful for reducing the retention of atherogenic lipoproteins in atherogenesis according to claim 1; and (ii) mixing the agent or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable excipient or diluent. Current U.S. Class: 514/789 Current International Class: 61; 01; 61

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Method